Esperanto for histones: CENP-A, not CenH3, is the centromeric histone H3 variant

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11179848

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Esperanto for histones: CENP-A, not CenH3, is the centromeric histone H3 variant


Received: 15 March 2013 / Revised: 17 March 2013 / Accepted: 17 March 2013 / Published online: 12 April 2013 © The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract The first centromeric protein identified in any species was CENP-A, a divergent member of the histone H3 family that was recognised by autoantibodies from patients with scleroderma-spectrum disease. It has recently been suggested to rename this protein CenH3. Here, we argue that the original name should be maintained both because it is the basis of a long established nomenclature for centromere proteins and because it avoids confusion due to the presence of canonical histone H3 at centromeres.

Responsible Editor: Conly Rieder.

W. C. Earnshaw (✉) · R. C. Allshire
Wellcome Trust Centre for Cell Biology, University of Edinburgh, Mayfield Road, Edinburgh EH9 3JR Scotland, UK
e-mail: bill.earnshaw@ed.ac.uk

B. E. Black
Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-6059, USA

K. Bloom · E. D. Salmon
Department of Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-3280, USA

B. R. Brinkley
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA

W. Brown
School of Biology, Medical School Queen’s Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK

I. M. Cheeseman
Whitehead Institute and Department of Biology, MIT, Nine Cambridge Center, Cambridge, MA 02142, USA

K. H. A. Choo
Chromosome Research, Murdoch Childrens Research Institute, Department of Paediatrics, Royal Children’s Hospital, Parkville, Victoria, Australia

G. P. Copenhaver
Department of Biology and the Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-3280, USA
Since the time of Linnaeus, scientific nomenclature has been based on precedent. Over the past several centuries, the tried and proven path to naming a species (or more recently, a protein) is first to discover one and then name it. In recent years, the rush of scientific progress, with multiple groups often simultaneously discovering and naming the same protein at the same time, has stressed the naming convention, and occasionally, groups of scientists have stepped in to rationalise the nomenclature.

In 2012, an article entitled ‘A unified phylogeny-based nomenclature for histone variants’ appeared in
the journal *Epigenetics and Chromatin* (Talbert et al. 2012). This article had a lengthy list of distinguished authors from the chromatin/epigenetics community and represents an effort to unify the histone nomenclature. This proposed simplification of naming histone variants follows on the heels of a number of previous distinguished efforts, including the rationalisation of the caspase nomenclature in 1996 (Alnemri et al. 1996), and a proposed standard nomenclature for the kinesin proteins (Lawrence et al. 2004). The caspase proposal was universally adopted almost immediately, as the ten different caspases were known by a host of confusing names at that time. The kinesin article also has been widely influential.

While the proposal to unify the histone nomenclature may have much to recommend it, with respect to the specialized histone H3 variant found at all active centromeres from budding yeast to human, we suggest, for the reasons detailed below, that the scientific community should maintain the original nomenclature.

P. S. Maddox  
Institute for Research in Immunology and Cancer (IRIC),  
Department of Pathology and Cell Biology, Université de Montréal, P.O. Box 6128, Station Centre-Ville, Montréal, QC H3C 3J7, Canada

R. L. Margolis  
Tumor Development Program, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA

H. Masumoto  
Department of Human Genome Research, Kazusa DNA Research Institute, 2-6-7 Kazusa-Kamatari, Kisarazu, Chiba 292-0818, Japan

A. D. McAinsh  
Centre for Mechanochemical Cell Biology, Division of Biomedical Cell Biology, Warwick Medical School, University of Warwick, Coventry, UK

B. G. Mellone · R. J. O’Neill  
Department of Molecular and Cell Biology, University of Connecticut, Storrs, CT 06209, USA

P. Meraldi  
Physiology and Metabolism Department, Medical Faculty, University of Geneva, Geneva, Switzerland

A. Musacchio  
Department of Mechanistic Cell Biology, Max Planck Institute of Molecular Physiology, Otto-Hahn-Straße 11, 44227 Dortmund, Germany

K. C. Scott · B. A. Sullivan  
Institute for Genome Sciences and Policy, Department of Molecular Genetics and Microbiology, Duke University, 101 Science Drive, Durham, NC 27708, USA

A. F. Straight  
Department of Biochemistry, Stanford University, Stanford, CA, USA

P. T. Stukenberg  
Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA 22908, USA

K. F. Sullivan  
Centre for Chromosome Biology, School of Natural Sciences, National University of Ireland, Galway, Galway, Ireland

C. E. Sunkel  
IBMC—Instituto de Biologia Molecular e Celular and ICBAS—Instituto de Ciencias Biomédica Abel Salazar, Universidade do Porto, Porto, Portugal

J. R. Swedlow  
Centre for Gene Regulation and Expression, College of Life Sciences, University of Dundee, Dundee DD1 5EH, UK

C. E. Walczak  
Medical Sciences Program, Indiana University, 915 East 3rd St., Bloomington, IN 47405, USA

P. E. Warburton  
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA

S. Westermann  
Research Institute of Molecular Pathology (IMP), Dr. Bohr Gasse 7, 1030 Vienna, Austria

H. F. Willard  
Institute for Genome Sciences and Policy, Duke University, 101 Science Drive, Durham, NC 27708, USA

L. Wordeman  
Department of Physiology and Biophysics, University of Washington School of Medicine, Seattle, WA 98195, USA

M. Yanagida  
G0 Cell Unit, Okinawa Institute of Science and Technology Graduate University, Tancha 1919-1, Onnason 904-0495 Okinawa, Japan

T. J. Yen  
Fox Chase Cancer Center, Philadelphia, PA 19111, USA

K. Yoda  
Bioscience and Biotechnology Center, Nagoya University, Nagoya, Aichi, Japan
(CENP-A) that was established for the centromeric histone H3 variant and avoid the usage of the misleading name (CenH3) proposed by Talbert et al. (2012).

The first known centromeric protein was discovered in human cells and named CENP-A in 1985 (Earnshaw and Rothfield 1985). CENP-A was shown to be a histone in 1991 by the late Doug Palmer, working with Bob Margolis (Palmer et al. 1991). This conclusion was subsequently confirmed when the protein was cloned by Kevin Sullivan and colleagues (Sullivan et al. 1994). CENP-A has been widely referred to by this name over the subsequent 28 years, and the CENP nomenclature has now been extended as far as CENP-X for well-studied proteins.

It has now been suggested (Talbert et al. 2012) that the name CENP-A should be superseeded by CenH3 so as to simplify multiple names now in use in multiple species for the histone H3 variant found only at active centromeres. The budding yeast homolog of CENP-A, CSE4, was described in 1995 (Stoler et al. 1995), as the product of the Cse4 gene, which was discovered in a screen for mutations that affected chromosome segregation. A later addition was the Drosophila homologue, discovered in 2000 by homology with CENP-A and then named Cid (Henikoff et al. 2000). It is an important distinction to Drosophila geneticists that Cid was not named because of a pre-existing named mutation (in which case this name would have been retained by tradition). To the contrary, Cid was identified on the basis of sequence similarity and was known from the outset to be the Drosophila variant of CENP-A.

The name proposed in Talbert et al., CenH3, adds an unnecessary layer of confusion that is scientifically misleading: its use implies that this protein is the centromeric histone H3. This is simply not correct. A range of studies has revealed that regional centromeres contain not only CENP-A, but also lots of canonical histone H3. This canonical centromeric histone H3 is not just a ‘stuffer’ or contaminant of centromere chromatin. Studies ranging from biochemical fractionation (Ando et al. 2002; Foltz et al. 2006; Hori et al. 2008) to high-resolution light microscopy (Blower et al. 2002; Sullivan and Karpen 2004; Ribeiro et al. 2010) reveal that centromeric canonical H3 nucleosomes are interspersed with CENP-A nucleosomes and that specific components (e.g. CENP-C and the histone fold-containing CENP-T/W complex-Nishino et al. 2012) that make meaningful contacts with centromeric H3-containing chromatin are important for kinetochore assembly and function (Ohzeki et al. 2012). In fact, the interspersed H3 chromatin may represent a distinct chromosome domain, as it is post-translationally modified in a pattern that is distinct from both canonical heterochromatin and euchromatin (Sullivan and Karpen 2004). Recognising this, the term ‘CenH3’ would more appropriately refer to centromere-associated canonical histone H3 than it does to the centromere-specific CENP-A. Correspondingly, it is inappropriate as a name for the histone H3 variant that is found exclusively at centromeres.

While we appreciate the overall efforts to unify the nomenclature of histones from a phylogenetic perspective, our view is that the proposal by the many chromatin-oriented authors of the Epigenetics and Chromatin article (Talbert et al. 2012) to rename CENP-A as CenH3 does not take into account the extensive preceding literature on centromeres or kinetochores, or the scientific confusion raised by such a change. It is notable that while the signatories to this Commentary have been primary contributors to the centromere literature and all of us have published (some extensively) on CENP-A, none of us was consulted concerning the Epigenetics and Chromatin nomenclature proposal. As systems and other forms of integrative biology become increasingly prevalent and communities that do not normally interact are brought into contact (and potential conflict), other nomenclature issues such as this will arise when the same protein means different things to diverse groups of scientists. Thus, the importance of cross-communication between communities and respect for precedence in naming (in this case, the precedence of the well-established CENP nomenclature) may actually increase over the next few years.

Bearing in mind the confusion that will inevitably arise over whether the term CenH3 refers to canonical histone H3 interspersed with CENP-A at centromeres or to the CENP-A itself, we recommend that the proposed name CenH3 be abandoned and that this important marker for centromeric chromatin should be referred to by the name originally given to it in 1985—CENP-A.

Acknowledgments WCE and RCA are Principal Research Fellows of the Wellcome Trust [grant numbers 073915 and 095021, respectively]. The Wellcome Trust Centre for Cell Biology is supported by core grant numbers 077707 and 092076. BEB is funded by NIH R01-GM082989, a Career Award in the Biomedical Sciences from the Burroughs Wellcome Fund and a Rita Allen Foundation Scholar Award.
KB is funded by grant R37 GM32238. IMC is funded by NIH grant GM088313. DWC is an Investigator of the Ludwig Institute, whose centromere work is supported by NIH grant GM074150. GPC thanks the National Science Foundation (MCB-1121563) for support. JGD is supported by NIH R01GM088371. TF is supported by the Cabinet Office, Government of Japan, through its ’Funding Program for Next Generation World-Leading Researchers’(LS122). RG is funded by an EMBO Installation Grant. DWG is funded by the European Community’s Seventh Framework Programme FP7/2007-2013 under grant agreements no. 241548 (Mitosys) and no. 258068 (Systems Microscopy) and from an ERC Starting Grant (no. 281198). DMG is supported by Cancer Research UK and the MRC. GJG is funded by NIH/NIGMS R01-50162, the Netherlands Organisation for Scientific Research (NWO-Vici-91812610). AL is supported by the Spanish Ministry of Economy (grants CSD2007-015 and 016.130.661). MAL is funded by NIH grant GM083988. SML is funded by NIH grant GM074150. GPC thanks the National Science Foundation for support. JRS is funded by BBSRC grant BB/H013024. CEW is funded by an EMBO Starting Grant (no. 152136) and from an ERC Starting Grant (no. 258068). CB is supported by the Swiss National Foundation, University of Geneva and the Foundation ‘La lumiére’. PTS is funded by NIH grant number-R01GM088313. DWC is an Investigator of the Ludwig Institute, whose centromere work is supported by NIH grant GM088313. GM69429, TY is funded by NIH grant GM083988, Core Grant CA06927, and an appropriation from the Commonwealth of Pennsylvania.

References


Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.